Related Experiment Video
Updated: Nov 19, 2025
Photothrombotic Ischemia: A Minimally Invasive and Reproducible Photochemical Cortical Lesion Model for Mouse Stroke Studies
Published on: June 9, 2013
LIM kinase inhibitor T56-LIMKi protects mouse brain from photothrombotic stroke
Svetlana V Demyanenko1, Anatoly Uzdensky1
1Laboratory of Molecular Neuroscience, Academy of Biology and Biotechnology, Southern Federal University, Rostov-on-Don, Russia.
Abstract:
Primary Objective: In an ischemic stroke, the damage spreads from the infarction core to surrounding tissues. The present work was aimed at the search of effective neuroprotectors that restrict injury propagation. Research Design: We studied possible protective effects of inhibitors of protein kinases LIMK2 (T56-LIMKi), DYRK1A (harmine), and tryptophan hydroxylase (4-chlorophenylalanine) on infarction size and morphology of peri-infarct area after photothrombotic stroke (a model of ischemic stroke) in mouse brain. Methods and Procedures: Photothrombotic stroke was induced by laser irradiation of mouse cortex after administration of photosensitizer Bengal Rose, which does not penetrate cells and remains in blood vessels. Under light exposure, it induces vessel occlusion. Infarct volume and histological changes in the cerebral cortex were evaluated 3, 7 and 14 days after photothrombotic impact. Main Outcomes and Results: Harmine and 4-chlorophenylalanine did not influence infarct volume and morphology of peri-infarct area in the mouse brain cortex after photothrombotic stroke. However, LIMK2 inhibitor T56-LIMKi significantly reduced infarct volume 7 and 14 days after photothrombotic stroke. It also increased the percent of normochromic neurons and decreased the fraction of altered cortical cells (hypochromic, hyperchromic and pyknotic neurons). Conclusions: T56-LIMK2i may be considered as a promising anti-stroke agent.
Insights
A novel LIMK2 inhibitor, T56-LIMKi, shows promise as an anti-stroke agent by significantly reducing infarct volume and improving neuronal health in a mouse model of ischemic stroke.
Area of Science:
- Neuroscience
- Pharmacology
- Cerebrovascular disease research
Background:
- Ischemic stroke causes progressive damage to brain tissue.
- Identifying effective neuroprotective agents is crucial to limit stroke-induced injury.
- Protein kinase inhibitors are being explored for neuroprotection.
Purpose of the Study:
- To investigate the neuroprotective potential of LIMK2 (T56-LIMKi), DYRK1A (harmine), and tryptophan hydroxylase (4-chlorophenylalanine) inhibitors.
- To evaluate their effects on infarct size and peri-infarct tissue morphology in a mouse model of ischemic stroke.
Main Methods:
- Photothrombotic stroke induced in mouse cortex using laser irradiation and Bengal Rose photosensitizer.
- Administration of T56-LIMKi, harmine, or 4-chlorophenylalanine.
- Infarct volume and histological changes assessed at 3, 7, and 14 days post-stroke.
Main Results:
- T56-LIMKi significantly reduced infarct volume at 7 and 14 days post-stroke.
- T56-LIMKi increased the proportion of normochromic neurons and decreased altered cortical cells.
- Harmine and 4-chlorophenylalanine showed no significant effects on infarct size or morphology.
Conclusions:
- T56-LIMKi demonstrates significant neuroprotective effects in a mouse model of ischemic stroke.
- T56-LIMK2i represents a potential therapeutic candidate for treating ischemic stroke.
- Further research into T56-LIMK2i as an anti-stroke agent is warranted.
